Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Max Gelman

Senior Editor

Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of biobucks in recent years.

The deal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Max Gelman

Senior Editor

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role